Loading...
•
Mar 31, 2024
Zimmer Biomet Q1 2024 Earnings Report
Reported an increase in net sales and adjusted diluted earnings per share in the first quarter of 2024 and reiterated full-year 2024 financial guidance.
Key Takeaways
Zimmer Biomet reported first quarter net sales of $1.889 billion, a 3.2% increase over the prior year, and a 4.4% increase on a constant currency basis. Diluted earnings per share were $0.84, and adjusted diluted earnings per share were $1.94. The company reiterated its full-year 2024 financial guidance.
First quarter net sales of $1.889 billion increased 3.2% and 4.4% on a constant currency basis.
First quarter diluted earnings per share were $0.84; adjusted diluted earnings per share were $1.94.
Company reiterates full-year 2024 financial guidance
Received FDA 510(k) clearance for the ROSA® Shoulder System and the Z1 Femoral Hip Stem.
Zimmer Biomet
Zimmer Biomet
Zimmer Biomet Revenue by Segment
Zimmer Biomet Revenue by Geographic Location
Revenue by Segment
Knees Revenue
CapyFin.comHips Revenue
CapyFin.comS.E.T. Revenue
CapyFin.comTech/Data/Surgical Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
The Company is reiterating its current full-year 2024 financial guidance.
Positive Outlook
- 2024 Reported Revenue Change 4.5% - 5.5%
- 2024 Constant Currency Revenue Change 5.0% - 6.0%
- Adjusted Diluted EPS $8.00 - $8.15
Challenges Ahead
- Foreign Currency Exchange Impact (0.5)%
Revenue & Expenses
Visualization of income flow from segment revenue to net income